NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -1.85 against a street estimate of -3.60 — a beat of 48.6%.
with an average price target of ₹264.00.
MIXED Q1 FY27 revenue grew 5.8% standalone, 8.2% consolidated. EBITDA margins expanded YoY but compressed QoQ. U.S. surged 62%, Europe flat, emerging markets declined. Waiting on critical FDA audit for sterile plant. Q1 FY27 U.S. growth masks sterile audit stall; Europe hindered by shipping timing, not demand; emerging markets expected temporary only. Analysts pressed FDA timing (no date), international market softness (cited timing/war, not demand), debt trajectory (INR 260cr near-term target). Management defended Q1 dips as temporary seasonal/logistical, reaffirmed long-term growth thesis conditional on audit clearance. 2026-07-28…
Full summary in the app.
| Document | Date |
|---|---|
| Annual report FY2026 INDOCO REMEDIES LIMITED - ANNUAL REPORT 2025-2026 SUMMARY HEADLINE NUMBERS • Revenue (Standalone): ₹1,63,353.81 Lakhs (with 45.10% from exports) • N | 2026-08-21 |
| Q1 FY27 earnings call INDOCO REMEDIES LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Standalone Revenue: INR4,081 million (Q1 FY27), up 5.8% YoY from INR3,856 million (Q1 F | 2026-08-04 |
| Q4 FY26 earnings call INDOCO REMEDIES LIMITED – FY '26 EARNINGS SUMMARY HEADLINE NUMBERS • Q4 FY'26 Standalone Net Revenues: INR 4,291 million vs INR 3,411 million (Q4 FY | 2026-05-11 |
| Quarterly results · Q4 FY26 INDOCO REMEDIES LIMITED – FINANCIAL SUMMARY Board Meeting, 7 May 2026 --- HEADLINE NUMBERS • Full Year FY2025-26 Revenue from Operations (Standalon | 2026-05-07 |
| Q3 FY26 earnings call INDOCO REMEDIES LIMITED – Q3 FY'26 SUMMARY HEADLINE NUMBERS • Standalone Net Revenues Q3 FY'26: INR 3,896 million vs INR 3,649 million (YoY +6.8%), | 2026-02-09 |
| Quarterly results · Q3 FY26 INDOCO REMEDIES LIMITED – FINANCIAL SUMMARY Q3 FY2025-26 (Quarter & Nine Months Ended 31 December 2025) --- HEADLINE NUMBERS • Q3 Revenue from Oper | 2026-02-03 |
| Q2 FY26 earnings call INDOCO REMEDIES LIMITED – Q2 FY'26 EARNINGS SUMMARY HEADLINE NUMBERS • Standalone net revenues Q2 FY'26: INR 4,293 million vs INR 3,946 million (Q2 | 2025-11-10 |
| Quarterly results · Q2 FY26 INDOCO REMEDIES LIMITED – FINANCIAL SUMMARY Q2 FY2025-26 (Quarter & Half-Year Ended 30 September 2025) --- HEADLINE NUMBERS STANDALONE RESULTS (Hal | 2025-11-06 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹0.20 / share ex-date Sep 10, 2026 | 2026-09-10 |
| Dividend | ₹0.20 / share ex-date Sep 4, 2025 | 2025-09-04 |
| Announcement | Date |
|---|---|
| Update on testing facility at Chhatrapati Sambaji Nagar, Aurangabad Indoco Remedies Limited, a pharmaceutical company, provided an update regarding its testing facility located in Chhatrapati Sambhaji Nagar (Aurangabad). The announcement does not specify the | 2026-04-13 |
| FDA approval received for API manufacturing facility at Patalganga Indoco Remedies Limited announced on December 11, 2025, that its Active Pharmaceutical Ingredient (API) manufacturing facility located at Patalganga has received an Establishment Inspection | 2025-12-11 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Indoco Remedies Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.